Position in ARGX
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$1,201,462
+$282,078 QoQ
Shares Held
1,295
+2.9% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#235
of 504 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ARGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PRINCIPAL SECURITIES, INC. holds $9,913,561 across 11 Biotechnology names. ARGX ranks #3 (12.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,982 | $2,971,438 | |
| 2 | RPRX |
Royalty Pharma plc
|
35,574 | $1,994,634 | |
| 3 | ARGX |
Argenx SE
This page
|
1,295 | $1,201,462 | |
| 4 | INSM |
INSMED Inc
|
6,728 | $717,339 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,028 | $640,999 | |
| 6 | EXEL |
Exelixis, Inc.
|
11,237 | $611,405 | |
| 7 | CORT |
Corcept Therapeutics Inc
|
5,720 | $497,354 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,389 | $418,130 |
All Filings in ARGX
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,201,462 | 1,295 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $919,384 | 1,259 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,309,359 | 1,557 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,233,937 | 1,673 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $595,868 | 1,081 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $477,635 | 807 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $496,305 | 807 | Shares | Sole | 2025-01-30 | |
| 2024-09-30 | $303,564 | 560 | Shares | Sole | 2024-10-28 | |
| 2024-06-30 | $236,091 | 549 | Shares | Sole | 2024-07-31 | |
| 2024-03-31 | $143,707 | 365 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $98,911 | 260 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||